{"title":"Article of Significant Interest Selected from This Issue by the Editors","authors":"","doi":"10.1128/cvi.00272-17","DOIUrl":null,"url":null,"abstract":"Effective Nanovaccines Protect against Lethal Burkholderia pseudomallei Infection Burkholderia pseudomallei, causative agent of melioidosis, exhibits high morbidity and mortality in humans. There are currently no vaccines available, and treatment options are limited. In the study by Muruato et al. (e00206-17), reverse vaccinology methods were used to identify novel, seroreactive Burkholderia antigens. Nanovaccines containing these proteins and Burkholderia lipopolysaccharide (LPS) generated high anti-protein and anti-LPS antibody titers in mice. One of these novel proteins, FlgL, provided 90% protection against lethal B. pseudomallei respiratory infection. Importantly, animals demonstrated a significant decrease in lung bacterial colonization compared to controls. These findings support further testing and development of nanovaccines against melioidosis.","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/cvi.00272-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0
Abstract
Effective Nanovaccines Protect against Lethal Burkholderia pseudomallei Infection Burkholderia pseudomallei, causative agent of melioidosis, exhibits high morbidity and mortality in humans. There are currently no vaccines available, and treatment options are limited. In the study by Muruato et al. (e00206-17), reverse vaccinology methods were used to identify novel, seroreactive Burkholderia antigens. Nanovaccines containing these proteins and Burkholderia lipopolysaccharide (LPS) generated high anti-protein and anti-LPS antibody titers in mice. One of these novel proteins, FlgL, provided 90% protection against lethal B. pseudomallei respiratory infection. Importantly, animals demonstrated a significant decrease in lung bacterial colonization compared to controls. These findings support further testing and development of nanovaccines against melioidosis.
期刊介绍：
Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
